Sergio  Traversa net worth and biography

Sergio Traversa Biography and Net Worth

Before joining Relmada, Dr. Traversa was the co-founder and CEO of Medeor Inc. a spinoff pharmaceutical company from Cornell University. Dr. Traversa has over twenty-five years of experience in the healthcare sector in the United States and Europe, ranging from management positions in the pharmaceutical industry to investing and strategic advisory roles. He has held financial analyst, portfolio management and strategic advisory positions at large U.S. investment firms specializing in healthcare, including Mehta and Isaly and Mehta partners, ING Barings, Merlin BioMed and Rx Capital.

Dr. Traversa was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he held the position of Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson & Johnson. Prior to Therakos, Dr. Traversa was at Eli Lilly, where he served as Marketing Manager of the Hospital Business Unit. He was also a member of the CNS team at Eli Lilly, where he participated in the launch of Prozac and the early development of Zyprexa and Cymbalta. Dr. Traversa started his career as a sales representative at Farmitalia Carlo Erba, the largest pharmaceutical company in Italy later sold to Pharmacia and now part of Pfizer.

Dr. Traversa holds a Laurea degree in Pharmacy from the University of Turin (Italy) and an MBA in Finance and International Business from the New York University Leonard Stern School of Business.

What is Sergio Traversa's net worth?

The estimated net worth of Sergio Traversa is at least $1.99 million as of September 9th, 2024. Traversa owns 299,603 shares of Relmada Therapeutics stock worth more than $1,989,364 as of March 25th. This net worth evaluation does not reflect any other assets that Traversa may own. Additionally, Traversa receives an annual salary of $1,790,000.00 as CEO at Relmada Therapeutics. Learn More about Sergio Traversa's net worth.

How old is Sergio Traversa?

Traversa is currently 64 years old. There are 2 older executives and 3 younger executives at Relmada Therapeutics. Learn More on Sergio Traversa's age.

What is Sergio Traversa's salary?

As the CEO of Relmada Therapeutics, Inc., Traversa earns $1,790,000.00 per year. Learn More on Sergio Traversa's salary.

How do I contact Sergio Traversa?

The corporate mailing address for Traversa and other Relmada Therapeutics executives is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. Relmada Therapeutics can also be reached via phone at (786) 629-1376 and via email at [email protected]. Learn More on Sergio Traversa's contact information.

Has Sergio Traversa been buying or selling shares of Relmada Therapeutics?

Sergio Traversa has not been actively trading shares of Relmada Therapeutics over the course of the past ninety days. Most recently, on Wednesday, September 11th, Sergio Traversa bought 51,407 shares of Relmada Therapeutics stock. The stock was acquired at an average cost of $2.99 per share, with a total value of $153,706.93. Following the completion of the transaction, the chief executive officer now directly owns 384,024 shares of the company's stock, valued at $1,148,231.76. Learn More on Sergio Traversa's trading history.

Who are Relmada Therapeutics' active insiders?

Relmada Therapeutics' insider roster includes Charles Casamento (Director), Chuck Ence (Chief Accounting and Compliance Officer), Paul Kelly (COO), Maged Shenouda (CFO), and Sergio Traversa (CEO). Learn More on Relmada Therapeutics' active insiders.

Are insiders buying or selling shares of Relmada Therapeutics?

In the last twelve months, Relmada Therapeutics insiders bought shares 9 times. They purchased a total of 1,366,626 shares worth more than $1,931,592.25. The most recent insider tranaction occured on December, 15th when CFO Maged Shenouda bought 11,665 shares worth more than $48,059.80. Insiders at Relmada Therapeutics own 20.7% of the company. Learn More about insider trades at Relmada Therapeutics.

Information on this page was last updated on 12/15/2025.

Sergio Traversa Insider Trading History at Relmada Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/11/2024Buy51,407$2.99$153,706.93384,024View SEC Filing Icon  
9/9/2024Buy55,579$2.71$150,619.09299,603View SEC Filing Icon  
1/31/2024Buy27,460$4.00$109,840.00244,024View SEC Filing Icon  
1/29/2024Buy31,541$3.71$117,017.11175,565View SEC Filing Icon  
12/8/2022Buy55,250$2.10$116,025.00144,024View SEC Filing Icon  
6/30/2022Sell16,012$19.13$306,309.5688,774View SEC Filing Icon  
3/9/2021Sell7,017$35.65$250,156.0598,774View SEC Filing Icon  
2/10/2021Sell1,930$35.28$68,090.4099,980View SEC Filing Icon  
2/8/2021Sell3,313$35.03$116,054.3999,980View SEC Filing Icon  
2/3/2021Sell3,278$35.07$114,959.4692,052View SEC Filing Icon  
1/26/2021Sell600$35.15$21,090.0079,563View SEC Filing Icon  
1/22/2021Sell2,170$35.58$77,208.6079,563View SEC Filing Icon  
12/15/2015Buy18,970$3.05$57,858.50339,322View SEC Filing Icon  
See Full Table

Sergio Traversa Buying and Selling Activity at Relmada Therapeutics

This chart shows Sergio Traversa's buying and selling at Relmada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Relmada Therapeutics Company Overview

Relmada Therapeutics logo
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Read More

Today's Range

Now: $6.59
Low: $6.19
High: $6.74

50 Day Range

MA: $4.58
Low: $3.55
High: $7.01

2 Week Range

Now: $6.59
Low: $0.24
High: $7.51

Volume

1,391,406 shs

Average Volume

1,555,888 shs

Market Capitalization

$483.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72